

Claims

1. The use of a 5-HT_{1B/1D} receptor agonist, or a pharmaceutically acceptable salt thereof, in the treatment or prevention of headache that results from administering an endothelin
5 receptor antagonist, or a pharmaceutically acceptable salt thereof.
2. The use of a 5-HT_{1B/1D} receptor agonist, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of headache that results from administering an endothelin receptor antagonist, or a pharmaceutically acceptable salt
10 thereof, in a warm-blooded animal, such as man.
3. A pharmaceutical composition which comprises a 5-HT_{1B/1D} receptor agonist, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the treatment or prevention of headache that results from
15 administering an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof.
4. The use according to claims 1-3 wherein the 5-HT_{1B/1D} receptor agonist is selected from zolmitriptan, sumatriptan, eletriptan, frovatriptan, naratriptan, rizatriptan and almotriptan or a pharmaceutically acceptable salt thereof.
20
5. The use according to claims 1-4 wherein the 5-HT_{1B/1D} receptor agonist is zolmitriptan or a pharmaceutically acceptable salt thereof.
6. The use according to claims 1-5 wherein the endothelin receptor antagonist is selected
25 from A-127722, atrasentan (ABT-627), BQ-123, BQ-788, BMS 182874, feloprentan, BSF 420627, FR139317, IPI-950, L-749,329, L-754,142, LU 110896, LU 110897, PD 156707, PD 155080, Ro 46-2005, bosentan (Ro 47-0203), SB 217242, SB 209670, TAK-044, YM598, sitaxsentan (TBC11251), ZD1611, ambrisentan, tezosentan, darusentan, *N*-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulphonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-*N*,3,3-trimethylbutanamide and *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (ZD4054) or a pharmaceutically acceptable salt thereof.
30
7. The use according to claims 1-6 wherein the endothelin receptor antagonist is selected from ZD4054.

8. A combination, comprising an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and a 5-HT_{1B/1D} receptor agonist, or a pharmaceutically acceptable salt thereof.

9. The combination according to claim 8 wherein the endothelin receptor antagonist is selected from A-127722, atrasentan (ABT-627), BQ-123, BQ-788, BMS 182874, feloprentan, BSF 420627, FR139317, IPI-950, L-749,329, L-754,142, LU 110896, LU 110897, PD 156707, PD 155080, Ro 46-2005, bosentan (Ro 47-0203), SB 217242, SB 209670, TAK-044, YM598, sitaxsentan (TBC11251), ZD1611, ambrisentan, tezosentan, darusentan, *N*-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulphonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-*N*,3,3-trimethylbutanamide and *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (ZD4054) or a pharmaceutically acceptable salt thereof.

10. The combination according to claims 8 or 9 wherein the 5-HT_{1B/1D} receptor agonist is selected from zolmitriptan, sumatriptan, eletriptan, frovatriptan, naratriptan, rizatriptan and almotriptan or a pharmaceutically acceptable salt thereof.

11. The combination according to any one of claims 8-10 wherein the endothelin receptor antagonist is ZD4054, or a pharmaceutically acceptable salt thereof, and the 5-HT_{1B/1D} receptor agonist is zolmitriptan, or a pharmaceutically acceptable salt thereof.

12. The combination according to any one of claims 8-11 for use as a medicament.

13. A pharmaceutical composition comprising the combination according to any one of claims 8-11, in association with a pharmaceutically acceptable diluent or carrier.

14. The use of the combination according to claims 8-11, in the manufacture of a medicament for use in the treatment of cancer, in a warm-blooded animal, such as man.

15. The use of the combination according to claims 8-11, in the manufacture of a medicament for use in the production of an anti-angiogenic effect, in a warm-blooded animal, such as man.

- 22 -

16. The use according to claim 14 wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric
5 cancer, head and neck cancer, renal cancer lymphoma and leukaemia.
17. The use according to claim 14 wherein the cancer is prostate cancer.
18. The use according to any one of claims 14 - 17 wherein the cancer is in a metastatic
10 state.
19. The use according to any one of claims 14 - 17 wherein the cancer is in a non-metastatic state.
- 15 20. The use according to any one of claims 14 - 17 wherein the cancer is renal, thyroid, lung, breast or prostate cancer that is producing bone metastases.